AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2019
Sep 9, 2019
33422_dirs_2019-09-09_8d1dfb99-6eb4-45b9-b0d4-8233e9d80dfb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-09-05
Reporting Person: AMELIO GILBERT F (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-09-05 | Common Stock | S | 30000 | $3.30 | Acquired | 124614 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold in multiple transactions at prices ranging from $3.30 to $3.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21